Compare SSM & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSM | PFSA |
|---|---|---|
| Founded | N/A | 2009 |
| Country | Germany | United States |
| Employees | 43 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 8.9M |
| IPO Year | N/A | N/A |
| Metric | SSM | PFSA |
|---|---|---|
| Price | $6.77 | $0.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 14.6M |
| Earning Date | N/A | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 122.22 |
| 52 Week Low | N/A | $0.05 |
| 52 Week High | N/A | $12.76 |
| Indicator | SSM | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 31.07 |
| Support Level | $6.72 | $0.08 |
| Resistance Level | $7.45 | $0.10 |
| Average True Range (ATR) | 0.36 | 0.02 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 35.14 | 2.28 |
Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and Services includes Complete Solar Solutions, Solar Charge Controllers, Solar Modules, and Data Services and Engineering Services.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.